Perseus Proteomics, Inc. (JP:4882) has released an update.
Perseus Proteomics Inc. has recorded a mix of non-operating income, expenses, and extraordinary losses in the first quarter of fiscal year 2025, including foreign exchange gains, share issuance costs, taxes, dues, and an impairment loss on non-current assets. These financial activities have already been incorporated into the company’s recently announced quarterly financial results.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.
